Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
KYV-101 by Kyverna Therapeutics for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According...
KYV-101 by Kyverna Therapeutics for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According...
KYV-101 by Kyverna Therapeutics for Myasthenia Gravis: Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...
KYV-101 by Kyverna Therapeutics for Lupus Nephritis: Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase...
KYV-101 by Kyverna Therapeutics for Lupus Nephritis: Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase...